Brief: Evelo Biosciences Provides Clinical Updates

Evelo Biosciences

26/04/2023 12:32

April 26 (Reuters) - Evelo Biosciences Inc  EVLO.O :
    * EVELO BIOSCIENCES PROVIDES CLINICAL UPDATES
    * EVELO BIOSCIENCES INC - TOPLINE DATA FROM FOURTH COHORT OF
EDP1815 PHASE 2 TRIAL IN ATOPIC DERMATITIS DID NOT MEET PRIMARY
ENDPOINT
    * EVELO BIOSCIENCES INC - WILL FOCUS ON DEVELOPMENT OF
EXTRACELLULAR VESICLES
    * EVELO BIOSCIENCES INC - FIRST EV CANDIDATE, EDP2939, IN
PHASE 2
MODERATE PSORIASIS STUDY FULLY ENROLLED; DATA ANTICIPATED IN
EARLY Q4 2023
    * EVELO BIOSCIENCES INC - WILL CEASE FURTHER DEVELOPMENT OF
EDP1815 IN ATOPIC DERMATITIS, FOLLOWING A WIND-DOWN OF STUDY
    * EVELO BIOSCIENCES INC - BELIEVE EDP2939 MAY HAVE GREATER
POTENTIAL ACTIVITY THAN EDP1815 IN PSORIASIS, WITH SIMILAR
TOLERABILITY
    * EVELO BIOSCIENCES - PRIORITIZING INVESTMENT IN EV PLATFORM
AND
IN EDP2939 CLINICAL DEVELOPMENT AND ARE REDUCING WORKFORCE TO
SAVE COSTS

Source text for Eikon:  ID:nGNX6VYPhg 
Further company coverage:  EVLO.O